# **OpenADMET-ExpansionRx-Blind-Challenge**

This repository describes my submission to the OpenADMET-ExpansionRx Blind Challenge

* Author: Mingning (Nancy) Zhu; Donghai Zhao  
* Date: January 2026

## **Methodology Report**

Algorithms:

* KERMT: [NVIDIA-Digital-Bio/KERMT: KERMT is a pretrained graph neural network model for molecular property prediction](https://github.com/NVIDIA-Digital-Bio/KERMT).

Additional Molecular Features

* RDKit 2D Descriptors generated by cuik\_molmaker

Additional Data

* We incorporated additional public datasets into the training data for the OpenADMET endpoints below. Our data-processing scripts follow the strategies described in Ref. \[1\].  
  * LogD  
    * literature datasets and public repositories. \[2–4\]  
    * ChEMBL assays (ChEMBL IDs: 3301363, 3431936). \[5\]  
  * KSOL (kinetic solubility)  
    * Polaris Drug Discovery Dataset. \[6\]  
    * Varnek et al. replication dataset; we used the curated subset of kinetic solubility measurements from Boehringer Ingelheim Pharma GmbH & Co. and Chimiothèque Nationale Essentielle. \[7\]  
  * HLM CLint (human liver microsomal clearance)  
    * Biogen dataset. \[8\]  
    * Polaris Drug Discovery dataset. \[6\]  
    * ChEMBL assays (ChEMBL IDs: 1924275, 2013638, 2168486, 3091165, 3301370, 3301372, 3788415, 3803440, 4706204, 4810045, 4834037). \[5\]  
    * PharmaBench dataset. \[11\]  
  * MLM CLint (mouse liver microsomal clearance)  
    * Polaris Drug Discovery Dataset. \[6\]  
    * ChEMBL assays (ChEMBL IDs: 1862765, 3803439, 4706205). \[5\]  
    * PharmaBench dataset. \[11\]  
  * Caco-2 Papp A→B  
    * OPERA dataset. \[9\]  
    * Therapeutics Data Commons (TDC) dataset. \[10\]  
  * MPPB  
    * Biogen dataset. \[8\]  
    * OPERA dataset. \[9\]  
    * TDC dataset. \[10\]  
* We also incorporated the following additional endpoints for multitasking:  
  * MDCK Effluc Ratio, Human Plasma Protein Binding: % Unbound, Rat Plasma Protein Binding: % Unbound from Biogen dataset. \[8\]  
  * Fraction unbound in human plasma (fu,p) from OPERA dataset. \[9\]  
  * Human Plasma Protein Binding Rate from the TDC dataset. \[10\]  
  * MDR1\_MDCKII from the Polaris Drug Discovery Dataset. \[6\]  
  * RLM CLint from PharmaBench dataset. \[11\]  
  * CYP (cytochrome P450) metabolism endpoints from PharmaBench dataset. \[11\]

Description of the train process

* For the six tasks: LogD, KSOL, MLM CLint, HLM CLint, Caco-2 Permeability Efflux, and Caco-2 Permeability Papp A\>B, we found that training with 20 endpoints together in a multi-task setting leads to improved performance.   
* For MPPB and MBPB, we only used single-task training.   
* For MGMB, we found that training with the following tasks together improves the effect on MGMB: log10\_MBPB, log10\_MGMB, log10\_MPPB, Biogen\_human\_Log\_PPB\_perc\_unb, Opera\_human\_Log\_fup, log10\_TDC\_PPB, and Biogen\_rat\_Log\_PPB\_perc\_unb.

Performance comments

* Graph neural network architectures with rdkit features have much better performance than tree-based methods (i.e. XGBoost) with rdkit features \+ molecular fingerprints.  
* Incorporating some QM features (solvation energy, HOMO-LUMO gap, dipole moment magnitude) directly doesn't lead to performance increase.

Code Availability: 

* The training scripts are available in [DonghaiZHAO-ZJU/OpenADMET-2026 at stable\_results\_v1](https://github.com/DonghaiZHAO-ZJU/OpenADMET-2026/tree/stable_results_v1).

### **References**

\[1\] Goossens, K.; Tricarico, G.; Hofmans, J.; Dréanic, M.-P.; de Cesco, S.; Lenselink, E. B. (2025). *ChemProp multi-task models for predicting ADME properties in the Polaris challenge*. ChemRxiv.

\[2\] Wang, J.-B., Cao, D.-S., Zhu, M.-F., Yun, Y.-H., Xiao, N., & Liang, Y.-Z. (2015). *In silico evaluation of logD7.4 and comparison with other prediction methods*. Journal of Chemometrics, 29(7), 389–398.

\[3\] Wang, Y., Xiong, J., Xiao, F., et al. (2023). *LogD7.4 prediction enhanced by transferring knowledge from chromatographic retention time, microscopic pKa and logP*. Journal of Cheminformatics, 15, 76\.

\[4\] Polaris Drug Discovery Dataset: [https://polarishub.io/competitions/asap-discovery/antiviral-admet-2025](https://polarishub.io/competitions/asap-discovery/antiviral-admet-2025).

\[5\] ChEMBL database: [https://www.ebi.ac.uk/chembl/](https://www.ebi.ac.uk/chembl/).

\[6\] Polaris Drug Discovery Dataset: [https://www.ebi.ac.uk/chembl/](https://www.ebi.ac.uk/chembl/).

\[7\] Baybekov, S., Llompart, P., Marcou, G., Gizzi, P., Galzi, J.-L., Ramos, P., Saurel, O., Bourban, C., Minoletti, C., & Varnek, A. (2023). *Données de réplication pour : Kinetic solubility: experimental and machine-learning modeling perspectives*.

\[8\] Fang, C., Wang, Y., Grater, R., Kapadnis, S., Black, C., Trapa, P., & Sciabola, S. (2023). *Prospective validation of machine learning algorithms for absorption, distribution, metabolism, and excretion prediction: An industrial perspective*. Journal of Chemical Information and Modeling, 63(11), 3263–3274.

\[9\] Mansouri, K., Grulke, C. M., Judson, R. S., & Williams, A. J. (2018). *OPERA models for predicting physicochemical properties and environmental fate endpoints*. Journal of Cheminformatics, 10(1), 1–19.

\[10\] Huang, K., Fu, T., Gao, W., Zhao, Y., Roohani, Y., Leskovec, J., Coley, C. W., Xiao, C., Sun, J., & Zitnik, M. (2021). *Therapeutics Data Commons: Machine learning datasets and tasks for drug discovery and development*. arXiv:2102.09548.

\[11\] Niu, Z., Xiao, X., Wu, W., et al. (2024). *PharmaBench: Enhancing ADMET benchmarks with large language models*. Scientific Data, 11, 985\.